AIDS · 2010 · 133 citations · 12 references
PharmacyPharmacologyPharmacotherapyClinical PharmacologyHiv ControlInfectious Disease PharmacotherapyAntiretroviral TherapyAntiviral TherapyDyslipidemia ManagementLipid DisordersLipid ManagementLipid-lowering TherapyHiv Antiretroviral TherapyLipid-lowering Drug EfficacyLow-density Lipoprotein Cholesterol LoweringLow-density Lipoprotein Cholesterol ReductionLow-density Lipoprotein ParticlesPilot Study DesignPlacebo Effect In TreatmentPlacebo-controlled Efficacy Assessment
Several studies have reported improvement in lipids after antiretroviral therapy switches to tenofovir disoproxil fumarate (TDF)-containing regimens. We assessed lipid-lowering effects of TDF by adding it to a stable antiretroviral therapy regimen in this double-blind, placebo-controlled crossover study. We demonstrated that nonhigh-density lipoprotein cholesterol, low-density lipoprotein cholestrol, and total cholestrol improved significantly over TDF vs. placebo treatment in HIV-infected individuals with dyslipidemia. Adding TDF to stable, virologically suppressive antiretroviral therapy regimens improved lipid parameters, supporting a lipid-lowering effect of TDF.
12
Scott M. Grundy · JAMA · 1993 · 27.9K citations
Impact of HIV Infection and HAART on Serum Lipids in Men
Sharon A. Riddler · JAMA · 2003 · 625 citations
Public Health, Infectious Disease Control, Hiv Prevention +15